Hana Biosciences Licenses North American Commercial Rights for Zensana to Par Pharmaceutical in a $50 Million Deal

Hana Biosciences, a biopharmaceutical company focused on advancing cancer care, announced that it has entered into an exclusive licensing agreement with Par Pharmaceutical for the development and commercialization of Zensana (ondansetron HCI) Oral Spray in North America.
Business Wire